Eloxx Pharmaceuticals, Inc.
ELOX · OTC
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | -0.07 | 0.13 | 0.68 |
| FCF Yield | -809.37% | -70.64% | -17.66% | -14.09% |
| EV / EBITDA | 0.06 | -0.32 | -4.51 | -5.61 |
| Quality | ||||
| ROIC | -1,263.55% | -184.20% | -150.24% | -97.27% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.88 | 0.52 | 0.81 | 0.77 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | 9.06% | -24.58% | 28.57% | -24.77% |
| Safety | ||||
| Net Debt / EBITDA | 0.18 | 0.45 | 0.39 | 0.14 |
| Interest Coverage | -17.66 | -52.44 | -23.74 | -31.28 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |